
Multispecific Trial Supply Stability Hinges On CDMO Agility
A conversation with Dr. Daniel Teper, Naya Therapeutics Not long ago, developing bi- and trispecific antibodies was fraught with complications, including process impurity and stability issues. Now, more companies can enjoy the fruits of a well- …